|Cetuximab binds to and competitively inhibits the activity of the epidermal growth factor receptor (EGFR).
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
As Bristol-Myers Squibb's original EU and US patents for cetuximab have expired, challengers of cetuximab's market position are developing biosimilar and/or biobetter cetuximab.
Celltrion's CT-P15 is a cetuximab biosimilar, intended for the treatment of colorectal cancer. MabTech-Sorrento's STI-001 is a proposed biobetter cetuximab (perhaps because synthesis in CHO cells creates a different glycosylation pattern to that of cetuximab which is made in mouse cells, and may be less likely to cause side-effects such as immunogenicity and hypersensitivity). STI-001 has completed Phase 3 clinical trial in China. Neither of these agents is associated with any clinical studies that are registered with ClinicalTrials.gov.